Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
261.11 (1y: +107%)
Market Cap 25.36 B P/E(ttm) 37.80
Enterprise Value 26.08 B P/B 20.50
REGN- NAS (USA)
Regeneron Pharmaceuticals, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$261.11
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 0.674
REGN's Cash to Debt is ranked lower than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 0.674 )
REGN' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: 0.67
Equity to Asset 0.599
REGN's Equity to Asset is ranked lower than
55% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. REGN: 0.599 )
REGN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.87
Current: 0.6
0.27
0.87
Interest Coverage 10.1
REGN's Interest Coverage is ranked lower than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 10.1 )
REGN' s 10-Year Interest Coverage Range
Min: 1   Max: No Debt
Current: 10.1
F-Score: 6
Z-Score: 19.64
M-Score: -0.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 33.20
REGN's Operating margin (%) is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. REGN: 33.20 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.6   Max: 188
Current: 33.2
-554.6
188
Net-margin (%) 54.4
REGN's Net-margin (%) is ranked higher than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. REGN: 54.4 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.7   Max: 54.4
Current: 54.4
-565.7
54.4
ROE (%) 60.2
REGN's ROE (%) is ranked higher than
98% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. REGN: 60.2 )
REGN' s 10-Year ROE (%) Range
Min: -85.2   Max: 60.2
Current: 60.2
-85.2
60.2
ROA (%) 36.1
REGN's ROA (%) is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. REGN: 36.1 )
REGN' s 10-Year ROA (%) Range
Min: -31.8   Max: 36.1
Current: 36.1
-31.8
36.1
ROC (Joel Greenblatt) (%) 41.00
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. REGN: 41.00 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.3   Max: 197.4
Current: 41
-1378.3
197.4
Revenue Growth (%) 25.9
REGN's Revenue Growth (%) is ranked higher than
85% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. REGN: 25.9 )
REGN' s 10-Year Revenue Growth (%) Range
Min: -18.1   Max: 56.1
Current: 25.9
-18.1
56.1
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

REGN Guru Trades in Q2 2012

Paul Tudor Jones 2,000 sh (New)
Frank Sands 6,142,048 sh (+6.5%)
Vanguard Health Care Fund 692,200 sh (unchged)
Pioneer Investments 18,000 sh (unchged)
Chuck Royce Sold Out
Jeremy Grantham Sold Out
RS Investment Management 5,270 sh (-12.31%)
Steven Cohen 49,320 sh (-14.02%)
» More
Q3 2012

REGN Guru Trades in Q3 2012

Jeremy Grantham 4,900 sh (New)
RS Investment Management 5,370 sh (+1.9%)
Pioneer Investments 18,000 sh (unchged)
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 522,200 sh (-24.56%)
Frank Sands 3,834,373 sh (-37.57%)
Steven Cohen 5,700 sh (-88.44%)
» More
Q4 2012

REGN Guru Trades in Q4 2012

Jim Simons 93,562 sh (New)
Steven Cohen 18,563 sh (+225.67%)
RS Investment Management 5,970 sh (+11.17%)
Pioneer Investments 19,000 sh (+5.56%)
Vanguard Health Care Fund 522,200 sh (unchged)
Jeremy Grantham 24,800 sh (unchged)
Frank Sands 3,223,869 sh (-15.92%)
» More
Q1 2013

REGN Guru Trades in Q1 2013

Vanguard Health Care Fund 1,412,100 sh (+170.41%)
Jeremy Grantham 30,600 sh (+23.39%)
RS Investment Management Sold Out
Steven Cohen 16,836 sh (-9.3%)
Pioneer Investments 13,900 sh (-26.84%)
Frank Sands 1,733,896 sh (-46.22%)
Jim Simons 31,162 sh (-66.69%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2013-03-31 Reduce -46.22%1.02%$158.42 - $183.77 $ 263.6454%1733896
Vanguard Health Care Fund 2013-03-31 Add 170.41%0.62%$158.42 - $183.77 $ 263.6454%1412100
Frank Sands 2012-09-30 Reduce -37.57%1.2%$112.77 - $152.66 $ 263.6495%3834373
Vanguard Health Care Fund 2012-09-30 Reduce -24.56%0.09%$112.77 - $152.66 $ 263.6495%522200
Frank Sands 2012-06-30 Add 6.5%0.2%$108.78 - $143.87 $ 263.64110%6142048
Dodge & Cox 2012-03-31 Sold Out $57.83 - $119.96 $ 263.64186%0
Carl Icahn 2011-09-30 Sold Out 1.76%$44.96 - $72.19 $ 263.64349%0
Dodge & Cox 2011-09-30 Reduce -97.62%0.03%$44.96 - $72.19 $ 263.64349%9400
Dodge & Cox 2011-03-31 New Buy0.02%$32.61 - $44.68 $ 263.64624%375685
Seth Klarman 2011-03-31 Sold Out $32.61 - $44.68 $ 263.64624%0
Seth Klarman 2010-09-30 New Buy1.66%$21.36 - $26.74 $ 263.64998%1000000
Vanguard Health Care Fund 2010-06-30 New Buy0.09%$22.98 - $30.28 $ 263.64900%700000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price
September 8, 2012
Regeneron Pharmaceuticals (REGN) is an integrated biopharmaceutical company focusing on medicines for the treatment of serious medical conditions. Following its annual filing for 2011, the company stated its core business value: “Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies, to combine that foundation with our clinical development and manufacturing capabilities, and to continue to expand our commercialization capabilities in anticipation of possible regulatory approval and launch of one or more of our late-stage product candidates. Our long-term objective is to build a successful, integrated, multi-product biopharmaceutical company that provides patients and medical professionals with innovative options for preventing and treating human diseases.” Read more...
52-Week High Companies: BAM, REGN, TRV, WFC
August 20, 2012
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs: Brookfield Asset Management Inc. (BAM), Regeneron Pharmaceuticals Inc. (REGN), The Travelers Companies Inc. (TRV) and Wells Fargo & Company (WFC). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 37.80
REGN's P/E(ttm) is ranked higher than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 20.85 vs. REGN: 37.80 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.83   Max: 90.63
Current: 37.8
9.83
90.63
P/B 20.50
REGN's P/B is ranked lower than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. REGN: 20.50 )
REGN' s 10-Year P/B Range
Min: 1.42   Max: 29.92
Current: 20.5
1.42
29.92
P/S 19.00
REGN's P/S is ranked lower than
67% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. REGN: 19.00 )
REGN' s 10-Year P/S Range
Min: 2.07   Max: 55.57
Current: 19
2.07
55.57
PFCF 1864.90
REGN's PFCF is ranked lower than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. REGN: 1864.90 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2883
Current: 1864.9
9.29
2883
EV-to-EBIT 41.7
REGN's EV-to-EBIT is ranked lower than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. REGN: 41.7 )
REGN' s 10-Year EV-to-EBIT Range
Min: 4   Max: 2827.4
Current: 41.7
4
2827.4
PEG 28.4
REGN's PEG is ranked lower than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.35 vs. REGN: 28.4 )
REGN' s 10-Year PEG Range
Min: 9.27   Max: 28.7
Current: 28.4
9.27
28.7
Shiller P/E 21806.5
REGN's Shiller P/E is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. REGN: 21806.5 )
REGN' s 10-Year Shiller P/E Range
Min: 16038   Max: 23618
Current: 21806.5
16038
23618

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 49.8
REGN's Price/Net Current Asset Value is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. REGN: 49.8 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 15.4   Max: 167.3
Current: 49.8
15.4
167.3
Price/Tangible Book 20.6
REGN's Price/Tangible Book is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. REGN: 20.6 )
REGN' s 10-Year Price/Tangible Book Range
Min: 2.8   Max: 15.9
Current: 20.6
2.8
15.9
Price/Median PS Value 1.6
REGN's Price/Median PS Value is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. REGN: 1.6 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 3.6
Current: 1.6
0.2
3.6
Price/Graham Number 6.6
REGN's Price/Graham Number is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. REGN: 6.6 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.3   Max: 4.3
Current: 6.6
1.3
4.3
Earnings Yield (Greenblatt) 2.40
REGN's Earnings Yield (Greenblatt) is ranked higher than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. REGN: 2.40 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 2.4
1.3
24.9
Forward Rate of Return (Yacktman) -0.45
REGN's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. REGN: -0.45 )
REGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.8   Max: -0.5
Current: -0.45
-22.8
-0.5

Business Description

Regeneron Pharmaceuticals, Inc. was incorporated in January 1988 in the State of New York. It is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company currently has two marketed products: EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States for the treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD is the main cause of acquired blindness for people over the age of 65 in the United States and Europe; and ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available by prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The Company has 13 product candidates in clinical development, all of which were discovered in its research laboratories. Its Trap-based, late-stage programs are: EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as VEGF Trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment. The Company, together with its ex-U.S. collaborator Bayer HealthCare, is evaluating EYLEA in Phase 3 programs in patients with central retinal vein occlusion (CRVO), diabetic macular edema (DME), and choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The Company's manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 395,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 54,000 liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. The Company's competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potent
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 
52-Week High Companies: EC, MAT, ORLY, V, REGN Apr 16 2012 
Weekly Top Insider Sells: TJX, MON, REGN, and PNC Jan 16 2012 
Weekly Top Insider Sells: INTU, NEE, REGN, CAM Sep 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
Dodge & Cox Q1 Portfolio Update May 13 2011 
Regeneron Pharmaceuticals Inc. (REGN) SVP F&A, CFO, Treas & Asst Sec Murray A Goldberg sells 4,569 S Feb 18 2011 

More From Our Partners
Sanofi/REGN Commence Enrollment - Analyst Blog May 15 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial